The changing landscape in the treatment of metastatic castration-resistant prostate cancer - Abstract

The past few years have brought increasing advances in the therapeutic management of metastatic castration-resistant prostate cancer with the approval of several agents, including vaccine therapy with sipuleucel-T, second-line chemotherapy with cabazitaxel, the bone-targeted pharmaceutical denosumab, and the novel antiandrogen therapy abiraterone acetate.

There are ongoing developments with other agents in the pipeline such as MDV3100 and alpharadin that have shown promising results. This review describes the clinical trials that brought about the drug approvals of various agents and offers some insights regarding a rational approach to optimal treatment sequencing for these drugs since national guidelines are currently lacking.

Written by:
El-Amm J, Aragon-Ching JB.   Are you the author?
Division of Hematology and Oncology, Department of Medicine, George Washington University Medical Center, Washington, DC, USA.

Reference: Ther Adv Med Oncol. 2013 Jan;5(1):25-40.
doi: 10.1177/1758834012458137


PubMed Abstract
PMID: 23323145

 

Go "Beyond the Abstract" - Read an article written by the authors for UroToday.com